People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

Study suggests inability to identify blood in urine may delay diagnosis and reduce surviva ...

As soon as the urologist said, oh it’s cancer…that is an eye-opener,” says Mark Stiegler, reflecting on his diagnosis six ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...